Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years old or older at the time of screening.
- Your cancer must have been confirmed by a tissue or cell sample test (such as a biopsy).
- Your cancer must be at an advanced stage and still growing or spreading at the time you enter the study.
- Your blood, liver, kidneys, and other organs must be functioning well enough to meet the study's requirements (confirm with trial site for specific details).
- You must have a specific change (mutation) in certain genes related to DNA repair, known as homologous recombination repair genes (confirm with trial site for specific testing requirements).
Who may not be able to join:
- You may not be eligible if you have had major surgery within the 4 weeks before starting the trial treatment.
- You may not be eligible if you have cancer that has spread to the spinal cord or brain, unless it has been treated, is stable, causing no symptoms, and you have not needed more than a low dose of steroid medication for at least 4 weeks before the trial starts.
- You are not eligible if cancer has spread to the membranes surrounding the brain and spinal cord (a condition called leptomeningeal carcinomatosis).
- You are not eligible if you have, or show signs of having, certain blood or bone marrow conditions called myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: China 86+18503817651
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The number of subjects with adverse events/serious adverse events; The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.